Core Insights - Daré Bioscience has launched DARE to PLAY™ Sildenafil Cream, a first-of-its-kind topical arousal cream for women, now available in all 50 states, aimed at enhancing female sexual health and addressing a significant gender gap in medical solutions [1][2][15]. Product Overview - DARE to PLAY™ is a non-hormonal topical cream that increases genital blood flow within 10-15 minutes and improves arousal sensations based on clinical studies [1][12]. - The cream utilizes sildenafil, the same active ingredient found in Viagra®, but is specifically formulated for women, providing a new evidence-based tool for sexual health [12][13]. Telehealth and Accessibility - Telehealth consultations for obtaining prescriptions for DARE to PLAY™ are now available nationwide, allowing women to connect with healthcare providers conveniently [2][3]. - The DARE Health Hub, powered by Medvantx Pharmacy, facilitates secure online consultations, making it easier for women to access the product without in-person visits [3][4]. Market Opportunity - Approximately 20 million women in the U.S. face challenges related to genital arousal, with no FDA-approved therapeutics currently available to address this need, highlighting a significant market opportunity for DARE to PLAY™ [15]. - The product is manufactured in a 503B outsourcing facility, ensuring compliance with current Good Manufacturing Practice (cGMP) regulations, which supports its credibility and quality [11][13]. Pre-Fulfillment Prescription Period - During the pre-fulfillment prescription period, women can complete telehealth consultations to obtain prescriptions, which will be securely held until pharmacy dispensing begins [5][7]. - Benefits during this period include complimentary telehealth visits and discounts on initial orders and refills of DARE to PLAY™ [8][9]. Company Mission and Vision - Daré Bioscience is dedicated to closing the gap in women's health by providing science-based solutions for various health issues, including sexual health, menopause, and fertility [19][20]. - The company aims to shift the narrative around women's health by offering credible, evidence-backed products that meet the needs of women [20].

Core Insights - DARE to PLAY™ Sildenafil Cream is a groundbreaking female arousal cream designed to enhance genital blood flow and arousal sensations, marking significant progress in women's sexual health [1][2][4] - The product is the first evidence-backed sildenafil cream formulation for women, manufactured under current Good Manufacturing Practice (cGMP) regulations [3][6] - Daré Bioscience aims to address the long-standing gap in women's sexual health solutions, providing a scientifically validated option for women experiencing arousal challenges [5][10] Product Overview - DARE to PLAY™ utilizes sildenafil, the same active ingredient in Viagra®, applied topically to improve genital blood flow without systemic effects [4][6] - The cream is available for prescription in select states, with plans for broader availability in the coming months [7][10] - The product is supported by multiple clinical trials and peer-reviewed research, ensuring its efficacy and safety [9][10] Market Opportunity - An estimated 20 million women in the U.S. face challenges related to genital arousal, highlighting a significant unmet need in the market [10] - The introduction of DARE to PLAY™ provides access to a clinically supported product for this underserved demographic [10] - Daré Bioscience is committed to closing the gap in women's health by advancing science-based solutions across various areas, including sexual health [12][13]

Core Insights - Daré Bioscience, Inc. has announced a strategic collaboration with Rosy Wellness to support the marketing and awareness campaign for its DARE to PLAY Sildenafil Cream, aimed at enhancing women's sexual health [1][3][4] Company Overview - Daré Bioscience is a biopharmaceutical company focused on women's health, aiming to address unmet needs through innovative solutions [10] - The company is set to start recording revenue in the fourth quarter of 2025 with the launch of DARE to PLAY Sildenafil Cream, a topical formulation of sildenafil citrate [1][2] Product Details - DARE to PLAY Sildenafil Cream is designed to increase local blood flow to genital tissues, addressing female sexual arousal disorder [2][11] - The product is expected to be available by prescription in the U.S. as a compounded drug under Section 503B of the FDCA [2] Collaboration Highlights - The partnership combines Daré's clinical expertise with Rosy's extensive digital reach and community engagement, which includes over 250,000 women [1][3] - The collaboration will focus on educational outreach and destigmatizing conversations around female sexual health [3][5] Market Context - Female sexual health is identified as a significantly underserved area, with 65% of women reporting concerns with arousal [3][4] - The partnership aims to enhance sexual wellness education and access for women, addressing a historically stigmatized topic [5][8]